Government may announce guidelines for vaccination against children coronavirus Will be revealed by the end of next week. Nearly 70 percent of the country’s adult population has now received at least one dose. COVID-19 Vaccination.
Top government sources who were part of scientific discussions on this question told Naveen Bharat A decision on immunization of children, including prioritizing categories of recipients and framing of guidelines on the timeline for the phased rollout, will be taken in the first half of this month.
Sources also said that the results of clinical trials of Bharat Biotech covaxin It is expected to be submitted to the regulator “around October 20-21” for emergency use approval in children.
The National Expert Group on Vaccine Administration for Covid-19 (NEGVEC) is expected to receive scientific recommendations from the Covid-19 Standing Committee of the National Technical Advisory Group on Immunization (NTAGI) in the next few days, it has learned.
Sources said NEGVEC will “study and decide” which category of recipients Zydus Cadila’s three-dose ZyCoV-D DNA vaccine, approved for children over 12 years of age, can use in the first phase. will, the sources said.
As schools reopen, jabs are crucial
As schools and colleges reopen in phases, immunization of children, especially those with comorbidities, will be crucial. In the first half of this month, the government will present a blueprint for the process, including guidelines, priority and timelines for vaccination.
NEGVEC is co-chaired by Dr VK Paul, Head of India’s COVID-19 Task Force and Union Health Secretary Rajesh Bhushan.
NTAGI is the country’s apex advisory body on vaccination.
Sources said that NTAGI has examined scientific data on comorbidity among children and the size of this vulnerable group. On Zydus Vaccine, we are considering the NTAGI recommendation on which category of children to use it in the first phase. They have seen comorbidities. That (recommendation) should come any day now. Once it comes, we will study and take a decision,” he said.
The results of the Covaxin Phase 2–3 pediatric study are expected a week after the guidelines on immunization of children. The study is being conducted on healthy volunteers over 2 years of age at six sites across the country to evaluate safety, reactivity and immunogenicity.
The third vaccine to be tested in children in India is Kovovax, the Indian version of the COVID-19 vaccine developed by US-based Novavax, which will be manufactured by Serum Institute of India. This recombinant nanoparticle protein-based vaccine, technically called NVX-CoV2373, will be tested at 23 sites across the country. Organic E’s. test of Corbewax Also expected to occur in children at 10 sites in India.